Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Robert Wurm"'
Autor:
Florian Posch, Luka Brčić, Gudrun Absenger, Verena Schlintl, Nikolaus John, Robert Wurm, Philipp J Jost, Angelika Terbuch, Teresa Sassmann, Jörg Lindenmann, Melanie Fediuk, Philipp Douschan, Martin Zacharias, Lipika Kalson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible ex
Externí odkaz:
https://doaj.org/article/7b357905ef25400b8600961cad6d9dc2
Autor:
Maximilian Hochmair, Angelika Terbuch, David Lang, Christian Trockenbacher, Florian Augustin, Bahil Ghanim, Dominik Maurer, Hossein Taghizadeh, Christoph Kamhuber, Robert Wurm, Jörg Lindenmann, Petra Braz, Tatjana Bundalo, Merjem Begic, Johanna Bauer, Patrick Reimann, Nino Müser, Florian Huemer, Verena Schlintl, Daniela Bianconi, Bernhard Baumgartner, Peter Schenk, Markus Rauter, Konrad Hötzenecker
Publikováno v:
Cancers, Vol 16, Iss 14, p 2586 (2024)
This was a retrospective study of the profile and initial treatments of adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018–December 2021 at 16 leading hospital institutions in Austria, excluding patients e
Externí odkaz:
https://doaj.org/article/3e588c78b2714c87bb4a690e179356da
Autor:
Matthias Preusser, Erika Richtig, Florian Moik, Cihan Ay, Martin Pichler, Florian Posch, Armin Gerger, Lukas Koch, Thomas Bauernhofer, Thomas Winder, Dominik A Barth, Sarah Steinlechner, Marie-Christina Mayer, Amelie M Sandner, Franziska Berton, Verena Schlintl, Nikolaus John, Robert Wurm, Patrick Reimann, Christoph Wohlkönig, Philipp J Jost, Angelika Terbuch, Jakob Michael Riedl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background C reactive protein (CRP) kinetics have recently been suggested as predictive biomarkers for the efficacy of immune checkpoint inhibitor (ICI) therapy in selected cancer types. The aim of this study was to characterize early CRP kinetics as
Externí odkaz:
https://doaj.org/article/a40a1d9c33b346768e290b28474e9d93
Autor:
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, Elizabeth Dudnik, Anna Eisert, Sayed M. S. Hashemi, Urska Janzic, Waleed Kian, Katja Mohorcic, Saara Mohammed, Maria Silvoniemi, Sacha I. Rothschild, Christian Schulz, Claas Wesseler, Alfredo Addeo, Karin Armster, Malinda Itchins, Marija Ivanović, Diego Kauffmann-Guerrero, Jussi Koivunen, Jonas Kuon, Nick Pavlakis, Berber Piet, Martin Sebastian, Janna-Lisa Velthaus-Rusik, Luciano Wannesson, Marcel Wiesweg, Robert Wurm, Corinna Albers-Leischner, Daniela E. Aust, Melanie Janning, Hannah Fabikan, Sylvia Herold, Anna Klimova, Sonja Loges, Yana Sharapova, Maret Schütz, Christoph Weinlinger, Arschang Valipour, Tobias Raphael Overbeck, Frank Griesinger, Marko Jakopovic, Maximilian J. Hochmair, Martin Wermke
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 7, p 3992 (2024)
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an
Externí odkaz:
https://doaj.org/article/6ed7bccf8a6a4049820a8177574fd8c6
Autor:
Martin Zacharias, Selma Konjic, Nikolaus Kratochwill, Gudrun Absenger, Angelika Terbuch, Philipp J. Jost, Robert Wurm, Jörg Lindenmann, Karl Kashofer, Franz Gollowitsch, Gregor Gorkiewicz, Luka Brcic
Publikováno v:
Cancers, Vol 16, Iss 5, p 903 (2024)
Due to the success story of biomarker-driven targeted therapy, most NSCLC guidelines agree that molecular reflex testing should be performed in all cases with non-squamous cell carcinoma (non-SCC). In contrast, testing recommendations for squamous ce
Externí odkaz:
https://doaj.org/article/0ae3b552babf4b58aea983434d5a1d50
Publikováno v:
Case Reports in Oncology, Vol 15, Iss 1, Pp 138-148 (2022)
Advances in the treatment of non-small-cell lung cancers (NSCLCs) lacking an actionable driver mutation have included the approval of immunotherapies, such as monotherapy or in combination with chemotherapy. However, limited evidence exists to guide
Externí odkaz:
https://doaj.org/article/737684948ee14058a7439a2c5493bb98
Autor:
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram Saad, Tanja Cufer, Hadas Gantz Sorotsky, Sayed M. S. Hashemi, Katja Mohorcic, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition ( MET ) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which
Externí odkaz:
https://doaj.org/article/0bbcd42c11e74cbfb91361945db11f28
Autor:
Angelika Terbuch, Gudrun Absenger, Gregor Gorkiewicz, Franz Gollowitsch, Karl Kashofer, Stefan Sauer, Selma Konjic, Robert Wurm, Luka Brcic, Jörg Lindenmann, Martin Zacharias
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Targeted treatment modalities for non-small cell lung carcinoma (NSCLC) patients are expanding rapidly and demand a constant adaptation of molecular testing strategies. In this regard, broad reflex testing via next-generation sequencing (
Autor:
Gudrun Absenger, Michael Fiegl, Claudia Wild, Horst Olschewski, Robert Wurm, Florian Kocher, Florian Endel, Peter Heininger, Melanie Zechmeister, Sabine Geiger-Gritsch, André Hermann, Martin Flicker, Georg Pall
Publikováno v:
Wiener klinische Wochenschrift. 133:1122-1130
As real-world data regarding immunotherapy for non-small cell lung cancer are lacking for Austria, we conducted a retrospective study in six hospitals to present data from real-world practice. Patients with metastatic non-small cell lung cancer were
Autor:
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram Saad, Tanja Cufer, Hadas Gantz Sorotsky, Sayed M. S. Hashemi, Katja Mohorcic, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair
Publikováno v:
Therapeutic Advances in Medical Oncology, 14. SAGE Publications Inc.
Therapeutic advances in medical oncology, vol. 14, pp. 1-22, 2022.
Illini, O, Fabikan, H, Swalduz, A, Vikström, A, Krenbek, D, Schumacher, M, Dudnik, E, Studnicka, M, Öhman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, H G, Hashemi, S M S, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, M J 2022, ' Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program ', Therapeutic Advances in Medical Oncology, vol. 14 . https://doi.org/10.1177/17588359221103206, https://doi.org/10.1177/17588359221103206
Therapeutic advances in medical oncology, vol. 14, pp. 1-22, 2022.
Illini, O, Fabikan, H, Swalduz, A, Vikström, A, Krenbek, D, Schumacher, M, Dudnik, E, Studnicka, M, Öhman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, H G, Hashemi, S M S, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, M J 2022, ' Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program ', Therapeutic Advances in Medical Oncology, vol. 14 . https://doi.org/10.1177/17588359221103206, https://doi.org/10.1177/17588359221103206
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition ( MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db862aef7575b35683811d5d7626aa21
https://research.vumc.nl/en/publications/592f783c-ba18-49d9-bc6f-f98cf8baa811
https://research.vumc.nl/en/publications/592f783c-ba18-49d9-bc6f-f98cf8baa811